Crude incidence rates and 95% CIs for ARIA-H <10 mm among those receiving bapineuzumab or placebo by the interval time from initiation of therapy
| Interval | Rate/100 person-years | Bapineuzumab | Rate/100 person-years | Placebo | ||
|---|---|---|---|---|---|---|
| LL 95% CI | UL 95% CI | LL 95% CI | UL 95% CI | |||
| ≤9 months | 12.20 | 7.65 | 19.90 | 4.38 | 1.50 | 12.11 |
| >9 months | 6.80 | 3.84 | 11.77 | 0.0 | 0.0 | 7.24 |
| Total | 9.22 | 6.41 | 13.08 | 2.55 | 0.87 | 7.23 |
ARIA-H, amyloid-related imaging abnormalities-haemosiderin; LL, lower limit; UL, upper limit.